Gyre Therapeutics, Inc. Files 8-K
Ticker: GYRE · Form: 8-K · Filed: Sep 10, 2025 · CIK: 1124105
| Field | Detail |
|---|---|
| Company | Gyre Therapeutics, Inc. (GYRE) |
| Form Type | 8-K |
| Filed Date | Sep 10, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-identity, name-change
TL;DR
Gyre Therapeutics (formerly Catalyst Biosciences) filed an 8-K, confirming its identity.
AI Summary
On September 10, 2025, Gyre Therapeutics, Inc. filed an 8-K report. The filing indicates a change in the company's name from Catalyst Biosciences, Inc. to Gyre Therapeutics, Inc. on August 20, 2015, and previously from Targacept Inc. in 2000. The company is located at 12770 High Bluff Drive, Suite 150, San Diego, CA 92130.
Why It Matters
This filing confirms the current corporate identity of Gyre Therapeutics, Inc. and its historical name changes, providing clarity for investors and stakeholders.
Risk Assessment
Risk Level: low — The filing is a routine corporate update and does not indicate any significant financial or operational changes.
Key Players & Entities
- Gyre Therapeutics, Inc. (company) — Registrant
- Catalyst Biosciences, Inc. (company) — Former Company Name
- Targacept Inc. (company) — Former Company Name
- September 10, 2025 (date) — Report Date
- August 20, 2015 (date) — Date of Name Change
- 2000 (date) — Date of Name Change
- 12770 High Bluff Drive Suite 150 San Diego, CA 92130 (address) — Principal Executive Offices
FAQ
What is the current name of the registrant?
The current name of the registrant is Gyre Therapeutics, Inc.
When was the company formerly known as Catalyst Biosciences, Inc.?
The company changed its name from Catalyst Biosciences, Inc. on August 20, 2015.
What is the principal executive office address?
The principal executive office is located at 12770 High Bluff Drive, Suite 150, San Diego, CA 92130.
What is the filing date of this 8-K report?
The report is dated September 10, 2025.
What was a previous name of the company before Catalyst Biosciences, Inc.?
A previous name of the company was Targacept Inc., with a name change occurring in 2000.
Filing Stats: 427 words · 2 min read · ~1 pages · Grade level 11.1 · Accepted 2025-09-10 09:00:50
Filing Documents
- ef20055378_8k.htm (8-K) — 30KB
- ef20055378_ex99-1.htm (EX-99.1) — 43KB
- ef20055378_ex99-1slide1.jpg (GRAPHIC) — 66KB
- ef20055378_ex99-1slide2.jpg (GRAPHIC) — 406KB
- ef20055378_ex99-1slide3.jpg (GRAPHIC) — 180KB
- ef20055378_ex99-1slide4.jpg (GRAPHIC) — 162KB
- ef20055378_ex99-1slide5.jpg (GRAPHIC) — 217KB
- ef20055378_ex99-1slide6.jpg (GRAPHIC) — 190KB
- ef20055378_ex99-1slide7.jpg (GRAPHIC) — 164KB
- ef20055378_ex99-1slide8.jpg (GRAPHIC) — 189KB
- ef20055378_ex99-1slide9.jpg (GRAPHIC) — 192KB
- ef20055378_ex99-1slide10.jpg (GRAPHIC) — 157KB
- ef20055378_ex99-1slide11.jpg (GRAPHIC) — 187KB
- ef20055378_ex99-1slide12.jpg (GRAPHIC) — 48KB
- ef20055378_ex99-1slide13.jpg (GRAPHIC) — 194KB
- ef20055378_ex99-1slide14.jpg (GRAPHIC) — 142KB
- ef20055378_ex99-1slide15.jpg (GRAPHIC) — 158KB
- ef20055378_ex99-1slide16.jpg (GRAPHIC) — 191KB
- ef20055378_ex99-1slide17.jpg (GRAPHIC) — 170KB
- ef20055378_ex99-1slide18.jpg (GRAPHIC) — 189KB
- 0001140361-25-034506.txt ( ) — 4620KB
- gyre-20250910.xsd (EX-101.SCH) — 4KB
- gyre-20250910_lab.xml (EX-101.LAB) — 21KB
- gyre-20250910_pre.xml (EX-101.PRE) — 16KB
- ef20055378_8k_htm.xml (XML) — 4KB
01
Item 8.01 Other Events. On September 10, 2025, Gyre Therapeutics, Inc. (the "Company") made available an updated corporate presentation on the Company's website. A copy of the corporate presentation is filed herewith as Exhibit 99.1 and incorporated herein by reference.
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits . EXHIBIT INDEX Exhibit No. Description 99.1 Corporate Presentation, dated September 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GYRE THERAPEUTICS, INC. Date: September 10, 2025 By: /s/ Ping Zhang Name: Ping Zhang Title: Executive Chairman and Interim Chief Executive Officer